Zacks Research Analysts Increase Earnings Estimates for TBPH

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Analysts at Zacks Research raised their Q1 2027 earnings per share (EPS) estimates for Theravance Biopharma in a research report issued to clients and investors on Wednesday, April 23rd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their previous forecast of ($0.41). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s FY2027 earnings at ($0.77) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.33.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $9.50 on Monday. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $10.90. The company has a market capitalization of $475.01 million, a PE ratio of -9.41 and a beta of 0.14. The business has a 50-day moving average of $9.10 and a 200-day moving average of $9.22.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares of the company’s stock, valued at approximately $3,330,342. This represents a 1.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its stake in Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after buying an additional 48,316 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Theravance Biopharma by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock worth $2,151,000 after buying an additional 7,620 shares during the period. Jane Street Group LLC boosted its position in shares of Theravance Biopharma by 1.1% in the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 1,640 shares during the period. Geode Capital Management LLC lifted its position in shares of Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company’s stock worth $8,121,000 after purchasing an additional 4,823 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Theravance Biopharma by 3.7% during the 4th quarter. Wellington Management Group LLP now owns 198,491 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 7,162 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.